# INFORMATION DISCLOSURE STATEMENT

Please acknowledge receipt of the following by affixing hereon the Patent and Trademark Office date stamp and returning this card to our office.

**Applicant(s):** Erion, et al. **Client:** Metabasis Therapeutics, Inc.
**Serial No.:** 09/978,454 **Filed:** October 15, 2001
**Attorney:** Lisa M. McGeehan

## NOVEL PRODRUGS FOR PHOSPHORUS-CONTAINING COMPOUNDS

**Docket No.:** 030727.0027.CON1
**Date of Deposit:** January 3, 2002
**Enclosure(s):** Transmittal Ltr (1 pg,); Information Disclosure Statement (2 pgs); PTO Form 1449 (8 pgs)

Please type a plus sign (+) inside this box → ☒

PTO/SB/21 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# TRANSMITTAL FORM

*(to be used for all correspondence after initial filing)*

| | |
|---|---|
| **Application Number** | 09/978,454 |
| **Filing Date** | October 15, 2001 |
| **First Named Inventor** | ERION |
| Group Art Unit | TBA |
| Examiner Name | TBA |
| Total Number of Pages in This Submission: 11 | Attorney Docket Number: 030727.0027.CON1 |

## ENCLOSURES *(check all that apply)*

- ☐ Fee Transmittal Form
  - ☐ Fee Attached
- ☐ Amendment/Reply
  - ☐ After Final
  - ☐ Affidavits/declaration(s)
- ☐ Extension of Time Request
- ☐ Express Abandonment Request
- ☒ Information Disclosure Statement
- ☐ Certified Copy of Priority Document(s)
- ☐ Response to Missing Parts/ Incomplete Application
  - ☐ Response to Missing Parts under 37 CFR 1.52 or 1.53
- ☐ Assignment Papers *(for an Application)*
- ☐ Drawing(s)
- ☐ Licensing-related Papers
- ☐ Petition
- ☐ Petition to Convert to a Provisional Application
- ☐ Power of Attorney, Revocation Change of Correspondence Address
- ☐ Terminal Disclaimer
- ☐ Request for Refund
- ☐ CD, Number of CD(s)
- ☐ After Allowance Communication to Group
- ☐ Appeal Communication to Board of Appeals and Interferences
- ☐ Appeal Communication to Group *(Appeal Notice, Brief, Reply Brief)*
- ☐ Proprietary Information
- ☐ Status Letter
- ☒ Other Enclosure(s) *(please identify below)*: Return Postcard

Remarks

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

| | |
|---|---|
| Firm or Individual name | Brobeck, Phleger & Harrison LLP |
| Signature | Lisa M. McGeehan, Reg. No. 41,185 |
| Date | 1-03-2002 |

## CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: ☐

| | | | |
|---|---|---|---|
| Typed or printed name | BARBARA J. KIELT | | |
| Signature | Barbara J. Kielt | Date | Jan. 3, 2002 |

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re the Application of:

Mark D. Erion, et al.

Serial No.: 09/978,454

Filed: October 15, 2001

For: NOVEL PRODRUGS FOR PHOSPHORUS-CONTAINING COMPOUNDS

Group Art Unit: TBA

Examiner: TBA

## INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In compliance with Applicants' duty under 37 CFR 1.56, the following information is brought to the attention of the Examiner. The items listed on the attached Form PTO 1449 were cited in Parent U.S. Patent Application number 09/392,352, filed September 8, 1999. Therefore, copies of the same are not enclosed. Applicants respectfully request that the documents be made of record in the above-referenced application. Applicants also request that the Examiner return an initialed copy of the attached Form PTO 1449 with the next Official Action indicating that the documents have been considered.

CERTIFICATE OF MAILING
(37 C.F.R. §1.8a)

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

BARBARA J. KIELT
Name of Person Mailing Paper

January 3, 2002
Date of Deposit

Barbara J. Kielt
Signature of Person Mailing Paper

C:\NrPortbl\SDILIB1\BK4\421555_1.DOC

This Information Disclosure Statement is believed to be timely in that it is being submitted under 37 CFR 1.97(b)(3) before the mailing of a first Office Action on the merits, whereby no fee is required. However, if counsel for Applicant is in error in this regard, the Commissioner is authorized to charge any required fee to counsel's Deposit Account No. **50-1273**.

Respectfully submitted,

BROBECK, PHLEGER & HARRISON LLP

Dated: 1-03-2002

By: Lisa M. McGeehan
Lisa M. McGeehan
Reg. No. 41,185

**BROBECK, PHLEGER & HARRISON LLP**
12390 El Camino Real
San Diego, CA 92130-2081
Telephone: (858) 720-2500
Facsimile: (858) 720-2555

FORM PTO-1449

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

| ATTY. D[illegible]T NO. | SERIAL NO. |
|---|---|
| 030727.[illegible]27.CON1 | 09/978,454 |
| APPLICANT: ERION | |
| FILING DATE: 10/15/01 | GROUP: TBA |

**U.S. PATENT DOCUMENTS**

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | FILING DATE |
|---|---|---|---|---|---|---|---|
| | AA | 3,018,302 A | 01.23.62 | Bielefeld, *et al.* | | | |
| | AB | 5,658,889 | 08/19/97 | GRUBER, *et al.* | 514 | 43 | 12/14/94 |

**FOREIGN PATENT DOCUMENTS**

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB CLASS | TRANSLAT YES | N |
|---|---|---|---|---|---|---|---|---|
| | AC | 91 19721 A1 | 12/26/91 | WO | | | | |
| | AD | 98 39344 A | 11/09/98 | WO | | | | |
| | AE | 98 39343 A | 11/09/98 | WO | | | | |
| | AF | 98 39342 A | 11/09/98 | WO | | | | |
| | AG | 0 180 276 A1 | 05/07/86 | EP | | | | |
| | AH | 3512781 A1 | 04/10/85 | DE | | | | |
| | AI | 0 353 692 B1 | 07.02.90 | EPO | | | | |
| | AJ | WO 96/01267 A | 18.01.96 | WO | | | | |
| | AK | 0 161 955 A | 21.11.85 | EPO | | | | |
| | AL | WO 97/03679 A | 06.02.97 | WO | | | | |
| | AM | 0 338 372 A | 25.10.89 | EPO | | | | |
| | AN | 0 481 214 A | 22.04.92 | EPO | | | | |

| EXAMINER: | DATE CONSIDERED: |
|---|---|

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

| | | OTHER DOCUMENTS (Including Author, Title, Date, ...ment Pages, etc.) |
|---|---|---|
| | AO | Alexander, *et al.*, "Preparation of 9-(2- Phosphonomethoxyethyl) Adenine Esters as Potential Prodrugs," Collect. Czech, Chem Commun., 59: 1853-1869 (1994) |
| | AP | Amin, *et al.*,"1-Hydroxy-3-(methylpentylamino)-propylidene-1, 1-bisphosphonic Acid as a Potent Inhibitor o Squalene Synthase," Arznemittelforschung. 46(8): 759-762 (1996) |
| | XA | Atiq, O.T., *et al.*, "Treatment of Unresectable Primary Liver cancer With Intrahepatic Fluorodeoxyuridine and Mitomycin C Through an Implantable Pump," *Cancer*, 69, 920-924 (1992) |
| | AQ | Auberson, *et al.*, "*N*-Phosphoalkyl-5-Aminomethylquinoxaline-2,3-Diones: *In Vivo* Active Ampa and NMDA(Glycine) Antagonists," Bioorg. Med. Chem. Lett., 9: 249-254 (1999) |
| | AR | Balthazor, *et al.* "Nickel-Catalyzed Arbuzov Reaction: Mechanistic Observation," J. Org Chem., 45: 5425-5426 (1980) |
| | XB | He, *et al.*, "Inactivation of Cytochrome P450 3A4 by Bergamottin, a Component of Grapefruit Juice," Chem Res. Toxicol 1998, 11, 252-259 |
| | AS | Bespalov, *et al.*, "Prologation of morphine analgesia by competitive NMDA receptor antagonist D-CPPene (SDZ EAA 494) in rats," Eur. J. Pharmacol. 351: 299-305 (1998) |
| | AT | Bijsterbosch, *et al.*, "Disposition of the acyclic Nucleoside Phosphonate (*S*)-9-(3-Hydroxy-2-Phosphonylmethoxypropyl) Adenine," Antimicrobial Agents and Chemotherapy. 42(5): 1146-1150 (1998) |
| | AU | Bird, *et al.*, "Synthesis of Novel *N*-Phosphonoalkyl Dipeptide Inhibitors of Human Collagenase," J. Med. Chem. 73: 158-169 (1994) |
| | AV | Brill and Landon, *et al.*, Chem Rev., 84: 577-585 (1984) |
| | AW | Campagne, *et al.* "Synthesis of Mixed Phosphate Diester Analogues of Dipeptides using BOP or PyBOP Reagents," Tetrahedron Lett., 34(42): 6743-6744 (1993) |

| EXAMINER: | DATE CONSIDERED: |
|---|---|
| EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant | |

| | | OTHER DOCUM... (Including Author, Title, Date, ...ient Pages, etc.) |
|---|---|---|
| | AX | Campbell, "The Synthesis of Phosphonate Esthers, an Extension of the Mitsunobu Reation," J. Org. Chem 52: 6331-6335 (1992) |
| | AY | Casara, *et al.*, "Synthesis of Acid Stable 5'-o-Fluorometer Phosphonates of Nucleosides," Bioorg. Med. Chem. Lett., 2(2): 145-148 (1992) |
| | AZ | Casteel, *et al.*, "Steric and Electronic Effects in the Aryl Phosphate to Arylphoshonate Rearrangement," Synthesis, 691-693 (1991) |
| | XC | Chen, *et al.*, , "Sensitization of Human Breast Cancer Cels to Cyclophosphamide and Ifosfamide by Transfer of al Liver Cytochrome P450 Gene," Cancer Research, 56, 1331-1340 (1996) |
| | XD | Chen and Waxman "Intratumoral Activation and Enhanced Chemotheraputic Effect of Oxazaphosphorines following Cytochrome P-450 Gene Transfer: Development of a Combined chemptherapy/Cancer Gene Therapy Strategy," Cancer Research, 55, 581-589 (1995) |
| | BA | De Lombaert, *et al.*, "N-Phosphomomethgyl Dipeptides and Their Phosphonate Prodrugs, a New Generation of Neutral Endopeptidase (NEP, EC 3.4.24.11) Inhibitors" J. Med. Chem 37: 498-511 (1994) |
| | BB | De Lombaert, *et al.*, "Pharmacological profile of a Non-Peptidic Dual Inhibitor of Neutral Endopeptidase 24.11 and Endothelin-converting enzyme," Biochem Biophys Res Commun 204: 407-412 (1994) |
| | BC | De Waziers, *et al.*, "Cytochrome P 450 Isoenzymes, Epoxide Hydrolase and Glutathione Transferases in Rat and Human Hepatic and Extrahepatic Tissues," J. Pharm. Exp. Ther. 253: 387-394 (1990) |
| | BD | Dearfield, *et al.*, "Analysis of the Genotoxicity of Nine Acrylate/Methacrylate Coumpounds in L5178Y Mouse Lymphoma Cells," Mutagenisis 4: 381-393 (1989) |
| | BE | Desos, *et al.*, "Structure-Activity Relationships in a Series of 2(1*H*)-Quinolones Bearing Different Acidic Function in the 3-Position: 6,7-Dichloro-2(1*H*)-oxoquinoline-3-phosphonic Acid, a New Potent and Selectiv AMPA/Kainate Antagonist with Neuroprotective Properties," 39: 197-206 (1996) |
| | BF | Dickson, *et al.*, "Orally Active Squalene Synthase Inhibitors: Bis((acyloxy)alkyl) Prodrugs of the α-Phosphonosulfonic Acid Moiety," J. Med. Chem. 39: 661-664 (1996) |

| EXAMINER: | DATE CONSIDERED: |
|---|---|
| EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant | |

| | | OTHER DOCUM... (Including Author, Title, Date, ...ent Pages, etc.) |
|---|---|---|
| | BG | Edmunson, *et al.*, "Cyclic Organophosphorus Compounds. Part 23. Configurational Assignments in the 4-Phenyl-1,3,2λ5-dioxaphosphorinane Series. X-Ray Molecular Structure of *cis*-2-Benzylamino-4-phenyl-1,3,2-dioxaphosphorinane 2-Oxide," J. Chem. Res. Synop., 5: 122-123 (1989) |
| | BH | Enriquez, *et al.*,"Conjugation of Aadenine Arabinoside 5'-Monophosphate to Arabinogalactan: Synthesis, Characterization, and Antiviral Activity," Bioconjugate Chem. 6: 195-202 (1995) |
| | BI | Farquhar, *et al.* "Biologically-Cleavable Phosphate Protective Groups: 4-Aclioxt-1,3,2-Dioxaphosphorinanes as Neutral Latent Precursors of Dianionic Phosphates," Tetrahedron Lett., 36(5): 655-658 (1995) |
| | BJ | Farquhar, *et al.*, "Biologically Reversible Phosphate-Protective Groups," Journal of Pharmaceutical Sciences 72(3): 324-325 (1983) |
| | BK | Farquhar, *et al.*, "Synthesis and Biological Evaluation of 9-[5'-(2-Oxo-1,3,2-oxazaphosphorinan-2-yl)-ß-D-arabinosyl]adenine and 9-[5'-(2-Oxo-1,3,2-dioxazaphosphorinan-2-yl)-ß-D-arabinosyl]adenine: Potential Neutral Precursors of 9-[ß-D-Arabinofuranosyl]adenine 5'-Monophosphate," J. Med. Chem. 28: 1358-1361 (1985) |
| | BL | Farquhar, *et al.*, "Synthesis and Biological Evaluation of Neutral Derivatives of 5-Fluoro-2'-deoxyuridine 5'-Phosphate," J. Med. Chem. 26: 1153-1158 (1983) |
| | BM | Fiume, *et al.*,"Inhibition of Hepatitis B Virus replication By Vidarbine Monophosphate Conjugated with Lactosaminated Serum Albumin," The Lancet 13-15 (1988) |
| | BN | Freed, *et al.*, "Evidence for Acyloxymethyyl Esters of Pyridmidenc, 5'-Deoxyribonucleotides as extraceullar sources of active a5'-deozyriboinucleotides in cultured cells," Biochemical Pharmacology, 38(19): 3193-3198 (1989) |
| | BO | Guida, *et al.*,"Structure-Based Design of Inhibitors of Purine Nucleoside Phosphorylase. 4. A Study of Phosphate Mimics," J. Med. Chem. 37: 1109-1114 (1994) |
| | BP | Hirayama, *et al.*, "Structure and conformation of a novel inhibitor of angiotensin I converting enzyme – a tripeptide containing phosphonic acid," Int. J. Pept. Protein Res. 38: 20-24 (1991) |
| | BQ | Hunston, *et al.*, "Synthesis and Biological Properties of Some Cyclic Phosphotriesters Derived from 2'-Deoxy-5-fluorouridine," J. Med. Chem. 27: 440-444 (1984) |

| EXAMINER: | DATE CONSIDERED: |
|---|---|

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

| OTHER DOCU... (Including Author, Title, Date, ...ient Pages, etc.) | | |
|---|---|---|
| | BR | Keenan, *et al.*, "Pathology Reevaluation of the Kociba *et al.* (1978) Bioassay of 2,3,7,8-TCDD: Implications for Risk Assessment," J. Tox. Envir. Health 34: 279-296 (1991) |
| | BS | Kelley, *et al.*, "[[(Guaninylalkl) phosphinico] methyl] phosphonic Acids. Multisubstrate Analogue inhibitors o Human Erythrocyte Purine Nucleoside Phosphorylase," J. Med. Chem. 38: 1005-1014 (1995) |
| | BT | Khamnei and Torrence, "Neighboring Group Catalysis in the Design of Nucleotide Prodrugs," J. Med. Chem. 39: 4109-4115 (1996) |
| | BU | Kryuchkov, *et al.*, Izv. Akad. Nauk SSSR, Ser. Khim. 6: 1201-1248 (1987) |
| | BV | Lok, *et al.*, "Neurotoxicity associated with adenine arabinoside monophosphate in the treatment of chronic hepatitis B virus infection," J. Antimicrob. Chemotherap. 14: 93-99 (1984) |
| | BW | Lu *et al.*, "Palladium-Catalyzed Reaction of Aryl Polyfluoroalkanesulfonates with *O,O*-Dialkyl Phosphonates Synthesis, 726-727 (1987) |
| | BX | McGuigan, *et al.*, "Kinase Bypass: A new strategy for Anti-Hiv Drug Design," Bioorganic & Medicinal Chemistry Letters, 3(6): 1207-1210 (1993) |
| | BY | Meier, *et al.*, "Cyclic Saligenyl Phosphotriesters of 2',3'-Dideoxy-2'3'-didehydrothymidine (d4t)," Bioorganic & Medicinal Chemistry Letters, 7(2): 99-104 (1997) |
| | BZ | Meijer, *et al.*,"Covalent and Noncovalent Protein Binding of Drugs: Implications for Hepatic Clearance, Storage, and Cell-Specific Drug Delivery," Pharm. Res. 6: 105-118 (1989) |
| | CA | Melvin, "An Efficient Synthesis of 2-Hydroxyphenylphosphonates," Tetrahedron Lett., 22(35): 3375-3376 (1981) |
| | CB | Meyer, *et al.*, "2"-*O*'-Acyl-6-thioinosine Cyclic 3', 5'-Phosphates as Prorugs of Thioinosinic Acid," J. Med. Chem. 22: 811-815 (1979) |

| EXAMINER: | DATE CONSIDERED: |
|---|---|
| EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant | |

| OTHER DOCUI. . (Including Author, Title, Date, .ient Pages, etc.) | | |
|---|---|---|
| | CC | Mitchell, *et al.*, "Bioreversible Protection for the Phospho Group: Bioactivation of the Di(4-acyloxybenzyl) and Mono(4-acyloxybenzyl) Phosphoesters of Methlphosphonate and Phosphonoacetate," J. Chem. Soc. Perkin Trans. 1 1992 |
| | CD | Mitsunobu, "The Use of Diethyl Azodicarboxylate and Triphenylphosphine in Synthesis and Transformatio of Natural Products," Synthesis, 1-28 (1981) |
| | CE | Moore, *et al.*, "Comparison of Mutagenicity results for Nine Coumpounds exaluated at the *hgprt* Locus in the Standard and Suspension CHO Assays," Mutagenisis 6: 77-85 (1991) |
| | XE | Murray, *et al.*, "Cytochrome P450 Expression is a common Molecular Event in Soft Tissue Sarcomas," J. Pathology, 171, 49-52 (1993) |
| | XF | Murray, *et al.*, "Cytochrome P450 CYP3A in human renal cell cancer," British J. Cancer, 79, 1836-1842 (1999) |
| | CF | Neidlein, *et al.*, "Mild Preparation of 1-Benzyloxyiminoalkylphosphonic Dichlorides: Application to the Synthesis of Cyclic Phosphonic Deisters and Cyclic Monoester Amides," Heterocycles 35: 1185-1203 (1993) |
| | CG | Nifantyev, *et al.*,"Synthesis and Structure of Some Stable Phospholane-Phospholanes," Phosphorus, Sulfu Silicon and Related Elements 113: 1-13 (1996) |
| | XG | Ogg, *et al.*, *Xenobiotica* 29, 269-279 (1999) |
| | CH | Ohashi, *et al.*, "Synthesis of Phosphonosphingoglycolipid found in Marine Snail Turbo Cornutus," Tetrahedron Lett., 29(10): 1189-1192 (1988) |
| | CI | Petrakis, *et al.*, Palladium-Catalyzed Substitutions of Triflates Derived from Tyrosine-Containing Peptides and Simpler Hydroxyarenes Forming 4-(Diethoxyphosphinyl) phenylalanines and Diethyl Arylphosphonates," J. Am. Chem. Soc., 109: 2831-2833 (1987) |
| | CJ | Redmore, "Phosphorus Derivatives of Nitrogen Heterocycles," J. Org. Chem., 35(12): 4114-4117 (1970) |

| EXAMINER: | DATE CONSIDERED: |
|---|---|
| EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant | |

| OTHER DOCUM... (Including Author, Title, Date, ...ient Pages, etc.) | | |
|---|---|---|
| | CK | Shaw & Cundy, "Biological Screens of PMEA Prodrugs," Pharm. Res. 10 (supp) s24 (1993) |
| | CL | Shih, *et al.*, "Preparation and Structures of 2-Dimethylamino-4-phenyl-1,3,2-dioxaphosphorinane-2-oxides, Bull. Inst. Chem. Acad. Sin. 41: 9-16 (1994) |
| | CM | Turner, "A General Appproach to the Synthesis of 1,6-,1,7-, and1,8-Naphthyridines," J. Org. Chem. 55(15) (1990) |
| | XH | Venook, A.P, "Treatment of Heptacellular Carcinoma: Too Many Options?" *J. Clin. Oncol.* 12, 1323-1334 (1994) |
| | CN | Vo-Quang, *et al.*, "(1-Amino-2-propenyl) Phosphonic Acid, an Inhibitor of Alanine Racemase and D-Alanine:D-Alanine Ligase.," J. Med. Chem. 29(4): 579-581 (1986) |
| | CO | Wagner, *et al.*, "Direct Conversion of Tetrahydropyranylated Alcohols to the corresponding Bromides," Tetrahedron Letters 30(5): 557-558 (1989) |
| | CP | Wallace, *et al.*, "Design and Synthesis of Potent, Selective Inhibitors of Endothelin-Converting Enzyme," J. Med. Chem. 41: 1513-1523 (1998) |
| | CQ | Walsh, *et al.*, "The Structures of Grantianine and Sceleratine," J. Am. Chem. Soc., 78: 4455-4458 (1956) |
| | XI | Watkins, *et al.*, Pharmacogenetics 4, 171-184 (1994) |
| | CR | Weibel, *et al.*, "Potentiating Effect of {2-[2-[(2-Amino-1,6-Dihydro-6-oxo-9H-Purin-9-yl)Methyl]-Phenyl]Ethenyl}-Phosphonic Acid (MDL 74,428), A Potent Inhibitor of Purine Nucleoside Phosphorylase, o the Antiretroviral Activities of 2', 3'- Dideoxyinosine Combined to Ribavirin in Mice," Biochem. Pharmacol. 48(2):245-252 (1994) |
| | CS | Wileman, *et al.*, "Receptor – mediated endocytosis," Biochem. J. 232: 1-14 (1985) |

| EXAMINER: | DATE CONSIDERED: |
|---|---|

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

| OTHER DOCUM... (Including Author, Title, Date, ...ment Pages, etc.) | | |
|---|---|---|
| | XJ | Yu, *et al.*, "In Vivo Modulation of alternative Pathways of P-450-Catalyzed Cyclophosphamide Metabolism: Impact on Pharmacokinetics and Antitumor Activity," *J. Pharm. Exp. Ther.* 288, 928-937 (1999) |
| | CT | Zon, "Cyclophosphamide Analogues," Progress in Med Chem. 19: 1205-1246 (1982) |
| | CU | Predvoditelev D. , *et al.*, "Glycero-2-hydroxymethylene phosphates" Journal of Organic Chemistry of the USSR (English Translation 13:1489-1492 (1977) |
| | CV | Predvoditelev, D. *et al.*, "Synthesis of lipids and their models on the basis of glycerol alkylene phosphites. V. Cyclic phosphatidylglycerol and phosphatidylhydroxyhomocholine" Journal of Organic Chemistry of the USSR (English Translation 17:1156-1165 (1981) |
| | CW | Hillers, *et al.*, "Analogs of pyrimidinemono- and polynucleotides. VI. Phosphates of 1-(1,4-dihydroxy-2-pentyl) thymine and 1-(1,3-dihydroxy-2-propyl) uracil" 89 (17): 1-264 (1978) |
| | CX | Farquhar, *et al.*, "5'-'4-(Pivaloyloxy)-1, 3, 2-dioxaphosphorinan –2-y]-2'-deoxy-5-fluorouridine: a membrane permeating prodrug of 5-fluoro-2'-deoxyuridylic acid (FDUMP)'" Journal of Medicinal Chemistry 38:488-495 (1995) |
| | | |

| EXAMINER: | DATE CONSIDERED: |
|---|---|
| EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant | |